Stockreport

BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology

Brainstorm Cell Therapeutics Inc.  (BCLI) 
Last brainstorm cell therapeutics inc. earnings: 11/14 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.brainstorm-cell.com
PDF A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS di [Read more]